Donanemab Maintains Cognitive Benefit 3 Years in Early Alzheimer Disease: Daily Dose
Your daily dose of the clinical news you may have missed.
Q&A: GLP-1 Monotherapy Is Not Enough—Jonathan Bonnet, MD, MPH, on the Lifestyle Prescription for Obesity
Obesity medicine expert Bonnet answers questions about the downsides of GLP-1 therapy for obesity management and how lifestyle medicine interventions will help.
What's the Mood Among Infectious Disease Experts Right Now? We Asked William Schaffner, MD
Schaffner describes the mood among his colleagues in infectious disease right now as anxious, perplexed, distressed, and angry. They expect the disruptions and their feelings to continue.
Addressing Pediatric Vaccine Hesitancy: Communication Strategies That Work
Effective pediatric vaccine conversations require trust and facts. Family physician Sarah Sams, MD, offers tips for addressing concerns without harming patient relationships.
Noninvasive Primary Care Screening Identifies Elevated LVEDP in Nearly 40% of High-Risk Patients
A new study reveals that noninvasive LVEDP screening can enhance heart failure detection and improve patient outcomes in primary care settings.
Nirsevimab Cuts RSV Risk in Healthy Newborns: Daily Dose
Does Intranasal Insulin Reach Critical Brain Areas Linked to Memory and Cognition?
Insulin delivered via nasal spray in this first-in-human PET imaging study was observed in 11 key brain areas relevant to cognitive decline, validating a new research avenue.
FDA Accepts Gepotidacin for Priority Review for the Treatment of Uncomplicated Urogenital Gonorrhea
FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.
Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study
The oral peptide that selectively targets IL-23 offers a novel approach to quelling the inflammatory process that underlies plaque psoriasis.
GLP-1 RAs Beat Metformin for Dementia Prevention in T2D: Daily Dose
Are the GLP-1 Agonists "Forever Drugs?" It's an Open Question, According to Jonathan Bonnet, MD, MPH
The obesity and lifestyle medicine specialist says while research on the question continues, a focus on optimizing nutritional health during treatment is essential.
The TikTok Doc Is In: But Will Your Patient Trust the Diagnosis?
Health information permeates social media platforms exposing Americans to advice, even when they don't want it. The good news? Not many trust it!
How Physicians Can Strengthen Vaccine Confidence During National Immunization Awareness Month
Board-certified family physician Sarah Sams, MD, urges physicians to actively engage their communities to build vaccine confidence and combat misinformation.
Excess Intake of Ultraprocessed Foods is Tied to Higher Cardiometabolic Risk, AHA Advisory Panel Says
The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.
Novel Plasma Assays That Selectively Detect Tau Characteristics Will Refine Clinical Study of Alzheimer Disease
The 2 new plasma assays to enhance Alzheimer’s disease research will support disease staging, predicting disease progression, and monitoring treatment outcome.
FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose
The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression
Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.
GLP-1 Medications Need a Permanent Place in Primary Care, Says Obesity Medicine Specialist
Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.
Use of Weight-Loss Drugs Increased Among US Adolescents After AAP Guideline Release
New data shows pediatric pharmacotherapy prescribing rose but remained infrequent, while nutrition counseling rates changed minimally.
Lilly's Oral GLP-1 Agonist Orforglipron Linked to Weight Reduction of 12.4% in Pivotal Phase 3 Trial
The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Addressing Pediatric Vaccine Hesitancy: Communication Strategies That Work")
